Molecular And Immunopathology Of Experimental And Clinic

$0Z01FY2003EYNIH

National Eye Institute

Investigators

Linked publications & trials

Paper 20482392 Paper 19608872 Paper 19438607 Paper 19422966 Paper 18974269 Paper 18572051 Paper 18528533 Paper 18523011 Paper 18495789 Paper 18474773 Paper 18461151 Paper 18438613 Paper 18436827 Paper 18379939 Paper 18354038 Paper 18308304 Paper 18299834 Paper 18288287 Paper 18242062 Paper 18195232 Paper 18179896 Paper 18079682 Paper 18037505 Paper 17985076 Paper 17846357 Paper 17675241 Paper 17671952 Paper 17652758 Paper 17651253 Paper 17558830 Paper 17525667 Paper 17440686 Paper 17212992 Paper 17126294 Paper 17082604 Paper 17079483 Paper 17070589 Paper 16832032 Paper 16827214 Paper 16799010 Paper 16793919 Paper 16782382 Paper 16777093 Paper 16765702 Paper 16754848 Paper 16625271 Paper 16585264 Paper 16462767 Paper 16445454 Paper 16414360 Paper 16352919 Paper 16289160 Paper 16163267 Paper 16083834 Paper 16049359 Paper 16043850 Paper 16009838 Paper 15972955 Paper 15944936 Paper 15791157 Paper 15746955 Paper 15728534 Paper 15579448 Paper 15534492 Paper 15377987 Paper 15375765 Paper 15368482 Paper 15364234 Paper 15326137 Paper 15325197 Paper 15240661 Paper 15223810 Paper 15208270 Paper 15094132 Paper 15078686 Paper 15060790 Paper 15019332 Paper 14985302 Paper 14662595 Paper 14632667 Paper 14609910 Paper 14597519 Paper 12928376 Paper 12917196 Paper 12869022 Paper 12733688 Paper 12697736 Paper 12525562 Paper 12523906 Paper 12208722 Paper 12147592 Paper 12091425 Paper 12082175 Paper 12022026 Paper 11980865 Paper 11899075 Paper 11884876 Paper 11867595 Paper 11859142 Paper 11709009

Abstract

The identity and topographic localization of ocular inflammatory, degenerative, and tumor cells and their products in patient specimens are analyzed by routine pathology, immunohistochemistry, in situ hybridization, microdissection and various molecular techniques including PCR, RT-PCR, and SNP. The application of cutting-edged pathological technology allows us to provide accurate pathological assessments of the disease, to guide us to select an appropriate therapy for the patient, and to better understand disease mechanism. In FY2002 we have continued and accomplished the following research: 1. Detection of Genes and Proteins in Ocular Lymphoma Cells: We continue to detect IgH gene rearrangemnts and vitreal IL-10 elevations being a useful adjunct for the diagnosis of primary intraocular B-cell lymphoma (PIOL). We found both the proteins and messengers of B-cell chemokines on RPE cells and the B-cell chemokine receptors on the PIOL cells, a possible mechanism for the PIOL localization between Bruch membrane and the RPE in the eye, which suggests targeting specific chemokines to treat PIOL. 2. New Pathology and Pathogenesis of Ocular Inflammation and Other Diseases: Using microdissection and PCR, we are able to detect various ocular pathogens associated with AIDS and diagnosed Propionibacterium acnes as causing endophthalmitis. We were the first group who reported teratoma-associated paraneoplastic retinopathy, abnormal neuroanatomy of the extraocular muscle tendon enthesis in patients with congenital nystagmus, and a unique pathology of congenital iridocorneal malformation in Rieger syndrome. 3. Experimental Models for Various Inflammatory Ocular Diseases: We continue to investigate the role of inflammatory mediators and cytokines in endotoxin-induced uveitis model (EIU). In collaboration with Drs. Caspi and Gery, several new modes of ocular inflammation were developed and published.

View original record on NIH RePORTER →